# PD-L1 in uveal melanoma

1 EU-approved indication in uveal melanoma needs a PD-L1 result: relatlimab + nivolumab (1st line, advanced).

## Approved indications

### PD-L1

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Relatlimab + nivolumab](https://oncolabels.com/drugs/relatlimab-nivolumab) (Opdualag) | PD-L1 TPS < 1% | Monotherapy | 1st line, advanced | Melanoma label; uveal melanoma was excluded from the trials; Aged 12 years and older |

## Label wording

- **Relatlimab + nivolumab** (Opdualag), Melanoma, 1st line, advanced: “Opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/uveal-melanoma/pd-l1